GEN-MKT-18-7897-A
Jan 26, 2018 | Biopharma, Blogs, Life Science Research, Proteomics, Technology | 0 comments
There’s no doubt about it, biopharma drug development is experiencing phenomenal growth and presents a variety of challenges not experienced in small molecule development. Some of these challenges are in the selective and sensitive quantitation of peptides and proteins in complex matrices. These large molecule analytes can suffer from matrix interferences, poor fragmentation and lack of quality unique peptides, or transitions compared to background, all which can affect the quality of analysis.
Traditional mass spectrometry (LC-MS/MS) assays continue to be highly effective for large molecule quantitation, but what if you need something more selective? What if you could easily ‘upgrade’ your already powerful mass spec? Thanks to advancements in mass spectrometry technology there is now an option that can be a game changer for peptide and protein quantitation workflows.
We are talking about the SelexION® Differential Mobility Separation (DMS) device. It offers a unique enhancement to your SCIEX mass spec, helping to remove sample interferences and separate isobaric peptide species, resulting in more sensitive and selective detection and quantitation of challenging large molecule targets.
Key Features of SelexION Technology for Peptide and Protein QuantitationUsing differential ion mobility spectroscopy (DMS) as an orthogonal dimension of separation prior to MS detection can provide many advantages:
Can provide enhanced specificity, selectivity, and sensitivity compared to LC-MS/MS alone
Do you want to know more? We thought you might, so we have worked on a library of tech notes to support you in your quest to achieve high performing peptide and protein quantitation workflows in drug discovery and development. Download the eBook and get access to technical papers, webinars, and so much more.
Find out about The Science Behind SelexION Differential Ion Mobility Technology and How SeleXION Addresses Your Biggest Analytical Challenges.
Download eBook >
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network